Australia's diagnostics hub to get upgraded lab for WHO work:
This article was originally published in Clinica
Australia is to establish a state-of-the-art diagnostics laboratory to house the World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza, to be located at the Victorian Infectious Diseases Reference Laboratory (VIDRL). The government has committed Aus$23m (US$17m) over four years to establish the new facility. The WHO centre, one of just five worldwide, is currently situated at the Melbourne site of pharma and diagnostics firm CSL, but will be taken over by VIDRL later this year and move to the new premises in 2007.
You may also be interested in...
Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).